TRAX compared with ANAB: revenue, margins and what each company keeps, and the suppliers and customers both name

TRAXFirst Tracks Biotherapeutics, Inc.

Mkt capRevenueRevenue

ANABAnaptysbio, Inc

Mkt capRevenueRevenue

Compare

TRAXFirst Tracks Biotherapeutics, Inc.

ANABAnaptysbio, Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

TRAX1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±13.3%▼−4.55%×0.34

ANAB

1 of 4at or beyond implied

Reportimpliedrealized× implied

May 13 '26±6.7%▼−4.41%×0.66

Q1 FY26±14.1%▲+14.61%×1.04

= impliedTRAX realized, solidANAB realized, hatchedOne scale, both sides: full bar = 17%× = |realized| ÷ impliedSource: market data

Q4 FY25

±10.0%

▲+9.76%

×0.98

Q3 FY25±16.7%▲+3.63%×0.22

TRAXFirst Tracks Biotherapeutics, Inc.

44.94▼−0.32%· post 44.94

Mkt cap$1.6BRevenue—Revenue—

ANABAnaptysbio, Inc

48.04▼−0.51%· post 47.31

ClosedNov 2 '26

Mkt cap$1.4BRevenue$26MQ1 FY26Revenue$235MFY25

Compare

ClosedNov 2 '26

TRAXFirst Tracks Biotherapeutics, Inc.

ANABAnaptysbio, Inc

44.94▼−0.32%post 44.94

Price

48.04▼−0.51%post 47.31

$1.6B

Mkt cap

$1.4B

—

Revenue

$26MQ1 FY26

—

Revenue

$235MFY25

TRAX44.94▼−0.32%vsANAB48.04▼−0.51%ClosedNov 2 '26